Teva Announces Approval And Shipment Of Generic Coreg® Tablets
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced that the U.S. Food and Drug Administration (FDA) has granted final approval for the company’s Abbreviated New Drug Application (ANDA) to market its Generic version of GlaxoSmithKline’s cardiovascular agent Coreg® (Carvedilol) Tablets, 3.125 mg, 6.25 mg, 12.5 mg and 25 mg. Shipment of this product will begin immediately.The brand product had annual sales of approximately $1. [click link for full article]
More: continued here
Filed under: Cardiovascular on September 12th, 2007